15% OFF GIFT VOUCHERS! SHOW ME

Close Notification

Your cart does not contain any items

The Political Economy of Global Healthcare Industries

States, Markets, and Power

Dylan Lee

$478.95   $383.10

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
Igi Global Scientific Publishing
11 March 2026
The global healthcare industry operates at the intersection of government authority, market forces, and unequal distributions of power that shape how care is financed, produced, and delivered. States regulate access, pricing, and standards, while multinational corporations, insurers, and investors influence innovation, supply chains, and labor conditions across borders. These interactions determine economic outcomes, who benefits from medical advances, and who remains underserved. Analyzing the political and economic structures that govern global healthcare may further reveal how power relations among states and market actors shape health systems, equity, and global health outcomes. The Political Economy of Global Healthcare Industries: States, Markets, and Power explores how states, markets, and global institutions shape the trajectory of healthcare industries. By situating healthcare within the frameworks of political economy, it moves beyond clinical or technological narratives to examine the forces of industrial policy, regulatory governance, capital flows, and strategic competition. This book covers topics such as drug manufacturing, business strategy, and government and law, and is a useful resource for business owners, medical and healthcare professionals, policymakers, academicians, researchers, and scientists.
Edited by:  
Imprint:   Igi Global Scientific Publishing
Dimensions:   Height: 254mm,  Width: 178mm,  Spine: 18mm
Weight:   735g
ISBN:   9798337374789
Pages:   450
Publication Date:  
Audience:   General/trade ,  ELT Advanced
Format:   Hardback
Publisher's Status:   Active

Dr. Dylan Lee holds an MD from a leading medical university, a PhD in Strategic Leadership from a U.S. research university, and an MBA from an accredited U.S. program. He currently serves as Chief Medical Officer at a global biopharmaceutical company, overseeing clinical development and multi-region regulatory strategy. His academic attribution rests on formal appointments in molecular medicine and immunology, graduate-level teaching in research design and clinical methodology, supervision of trainees, and contributions to peer-reviewed scholarship with service as a reviewer/editorial contributor. This scholarly base--methods-driven protocol design, transparent reporting standards, and evidence synthesis--directly underpins his industry leadership. In the healthcare and biopharma sector, he has led end-to-end translation from preclinical rationale to first-in-human and late-phase studies, directed IND/CTA authoring across U.S.-EU-Asia jurisdictions, and built cross-functional governance spanning medical, regulatory, pharmacovigilance, and biostatistics. He has run global, multi-site trials with risk-based monitoring and GxP quality systems, executed portfolio and indication-selection decisions tied to payer-relevant endpoints, and managed cross-border partnerships, diligence, and integration. By coupling clinical training and academic rigor with operational execution, he provides the kind of leadership that moves programs from mechanism to marketed value while meeting scientific, regulatory, and commercial thresholds.

See Also